Apyx Medical (APYX) Q2 2026 earnings

Published Aug 6, 2026

AI summary

Revenue $13.9M, up 22% from $11.4M a year ago.
GAAP EPS −$0.07 beat the −$0.08 consensus by $0.01, up from −$0.09 a year ago.
Total revenue grew 22% to $13.9 million in the second quarter of 2026.
Surgical Aesthetics segment sales rose 28% driven by the AYON platform and increased handpiece volume.
Net loss narrowed to $3.2 million compared to a $3.8 million loss in the prior year period.

Revenue

Reported

$13.9M

Consensus not captured before release

+22% YoY

EPS · GAAP (street basis)

Reported · Diluted EPS (GAAP, street basis)

−$0.07

Consensus −$0.08

Beat by $0.01

GAAP EPS: −$0.07

Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.

$59.0M–$60.0M

FY2026 revenue guidance

Next-quarter consensus not captured before release.

OEM segment sales decreased 12% due to lower volume to existing customers.
Operating expenses increased to $10.7 million from $9.7 million in the prior year period.

Source: Apyx Medical Corporation press release · SEC Form 8-K exhibit 99.1

Figures as stated in the company’s release; consensus from the provider named above. Not financial advice.